Influence of prognostic factors on survival in phase III, MPACT study of weekly nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer

Dr Josep Tabernero of the Vall d'Hebron University Hospital, Barcelona, Spain presented on the first day of the ESMO 15th World Congress on Gastrointestinal Cancer (3-6 July 2013, Barcelona, Spain) the results from a sub-study on influence of prognostic factors on overall- and progression-free survival from the MPACT phase III trial of weekly nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer. The most important predictors of longer overall survival and progression-free survival were higher Karnofsky performance status, age < 65 years, absence of liver metastases, and geographic region. Read more here.